Clinical Trial Update: A Prospective, Multicenter Study on Best Clinical Use of Imatinib in the Advanced Gastrointestinal Stromal Tumors [Phase 2]

View source ↗

Summary

A prospective, multicenter Phase 2 study evaluates the best clinical use of imatinib in advanced gastrointestinal stromal tumors. The trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• Gleevec (Imatinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Advanced Gastrointestinal Stromal Tumors | Phase 2 | Status: COMPLETED